Fortrea Holdings Valuation
Is FTRE1 * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of FTRE1 * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: FTRE1 * (MX$463.7) is trading below our estimate of fair value (MX$1426.37)
Significantly Below Fair Value: FTRE1 * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FTRE1 *?
Other financial metrics that can be useful for relative valuation.
What is FTRE1 *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$2.13b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.2x |
Enterprise Value/EBITDA | 27.4x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does FTRE1 *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 14.2x | ||
LAB B Genomma Lab Internacional. de | 1x | 8.2% | Mex$16.3b |
SKAN SKAN Group | 5.6x | 15.7% | CHF 1.8b |
1548 Genscript Biotech | 2.7x | 37.2% | HK$17.7b |
A141080 LigaChem Biosciences | 47.4x | 22.9% | ₩2.7t |
FTRE1 * Fortrea Holdings | 0.7x | 2.8% | Mex$2.1b |
Price-To-Sales vs Peers: FTRE1 * is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (14.2x).
Price to Earnings Ratio vs Industry
How does FTRE1 *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?
Price-To-Sales vs Industry: FTRE1 * is good value based on its Price-To-Sales Ratio (0.7x) compared to the Global Life Sciences industry average (3.7x).
Price to Sales Ratio vs Fair Ratio
What is FTRE1 *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.7x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate FTRE1 *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.